Abstract:Glucagon has plenty of effects via a specific glucagon receptor(GCGR) like elevating the blood glucose, improving fatty acids metabolism, energy expenditure and increasing lipolysis in adipose tissue. The most important role of glucagon is to regulate the blood glucose, but the emergent possibilities of hyperglycaemia is exist. Glucagon could also slightly activate glucagon-like peptide-1 receptor(GLP-1R), which lead to blood glucose lowering effect. This study aims to erase the likelihood of hyperglycaemia and to remain the inherent catabolic effects through improving GLP-1R activation and deteriorating GCGR activation so as to lower the bodyweight and show diabetes-protective effects. Firstly, twelve cysteine modified GLP-1/GCGR dual agonists were synthesized (1-12). Then, the GLP-1R/GCGR mediated activation and biological activity in normal ICR mice were comprehensively performed. Compounds substituted by cysteine at positions 22, 23 and 25 in glucagon were observed to be better regulators of the body weight and blood glucose. To prolong the half-lives of derivatives, various fatty side chain maleimides were modified to optimal glucagon analogues. Laurate maleimide conjugate 4d was the most potent. Administration of 1000 nmol/kg 4d once every two days for a month normalized adiposity and glucose tolerance in diet-induced obese (DIO) mice. Improvements in plasma metabolic parameters including insulin, leptin, and adiponectin were observed. These studies suggest that compound 4d behaves well in lowering body weight and maintaining energy expenditure without a chance of hyperglycaemia, 4d has strong clinical potential as an efficient GLP-1/GCGR agonist in the prevention and treatment of obesity and dyslipidemia. (C) 2017 Elsevier Masson SAS. All rights reserved.

Design, Synthesis and Crystallization of a Novel Glucagon Analog As a Therapeutic Agent

Structure of the glucagon receptor in complex with a glucagon analogue

Design and Synthesis of Conformationally Constrained Tri-Substituted Ureas As Potent Antagonists of the Human Glucagon Receptor

Design, Synthesis, And Biological Activity Of Novel Dicoumarol Glucagon-Like Peptide 1 Conjugates

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Molecular Insights into Ago-Allosteric Modulation of the Human Glucagon-Like Peptide-1 Receptor

Synthesis and Biological Evaluation of Glucagon-Like Peptide-1 Receptor Agonists.

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-like Peptide-1 Conjugates.

Α/sulfono-Γ-aapeptide Hybrid Analogues of Glucagon with Enhanced Stability and Prolonged in Vivo Activity

Computational Insight Into Conformational States Of Glucagon-Like Peptide-1 Receptor (Glp-1r) And Its Binding Mode With Glp-1

A Novel Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist Exhibits Weight-Lowering and Diabetes-Protective Effects.

A Novel Series of 4-Methyl Substituted Pyrazole Derivatives As Potent Glucagon Receptor Antagonists: Design, Synthesis and Evaluation of Biological Activities.

Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue

Novel Fatty Chain-Modified Glucagon-Like Peptide-1 Conjugates with Enhanced Stability and Prolonged in Vivo Activity.

Discovery and Investigation of A Novel Class of Thiophene-Derived Antagonists of the Human Glucagon Receptor

Novel Glucagon- and OXM-based Peptides Acting Through Glucagon and GLP-1 Receptors with Body Weight Reduction and Anti-Diabetic Properties.

Discovery of Cyclic Guanidines As Potent, Orally Active, Human Glucagon Receptor Antagonists

Site-specific Fatty Chain-Modified Exenatide Analogs with Balanced Glucoregulatory Activity and Prolonged in Vivo Activity.

A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects

Structural Modeling and in Silico Screening of Potential Small-Molecule Allosteric Agonists of a Glucagon-like Peptide 1 Receptor